XLS Consumer Health | Key figures € million Q1 – 2014 Q1 – 2013* Change in % * The previous year’s figures have been adjusted, see “The Merck Group and its divisions”. Total revenues 180.5 181.8 –0.7 Sales 180.2 181.7 –0.8 Operating result (EBIT) 36.7 36.8 – Margin (% of sales) 20.4 20.2 EBITDA 39.1 39.4 –0.8 Margin (% of sales) 21.7 21.7 EBITDA pre one-time items 41.3 39.3 5.0 Margin (% of sales) 22.9 21.6 Business free cash flow 16.2 20.8 –22.5 Development of total revenues and sales as well as results of operations In the first quarter of 2014, the Consumer Health division generated sales of € 180 million (Q1 2013: € 182 million). The [...]
[...] B segment, and Floratil®, a leading brand in the probiotic antidiarrheal segment in Brazil. As a result, the division has become significantly larger. Divisional sales for 2013 increased by approximately 55% to € 742 million. The transfer of the two strong brands makes better use of the potential of the consumer-oriented business model of Consumer Health. In addition, it increases the division’s exposure in Emerging Markets. This is a step in the division’s journey towards having at least three leading brands and achieving a market share of at least 3% in each of its key markets. The share of Consumer Health sales accounted for by Emerging Markets increased [...]
With the publication of the results of 2013, Merck provided a forecast of expected sales, EBITDA pre one-time items and business free cash flow for the Merck Group and its divisions for 2014. Owing to business performance in the first quarter of 2014, Merck confirms its forecast for the full year 2014 despite anticipated negative foreign exchange effects. The latter will stem mainly from the U.S. dollar and the Japanese yen, yet also from the Brazilian real, the Argentinean peso and additional currencies. Relative to the sales of the Merck Group, we therefore currently assume negative exchange rate effects of approximately 3–4% compared to the previous year. [...]
[...] a MUC1 antigen specific cancer immunotherapy in non-small-cell lung cancer (NSCLC). Based on the results of pre-clinical work and the ongoing Phase I trial of its C-Met kinase inhibitor, Merck Serono decided to embark on Phase I/II studies in the indications of non-small-cell lung cancer and hepatocellular carcinoma. Studies in both indications were initiated in the first quarter. Following the demonstration of clinical activity of Sym004, a mixture of two chimeric monoclonal antibodies against different parts of the Epidermal Growth Factor Receptor (EGFR), in a clinical study, Merck decided to start a further Phase II study. In the field of Fertility, a Phase III [...]
[...] both increasing life expectancy and in part also to growing prosperity in this region, along with the resulting changes in lifestyle and eating habits. Merck Serono is continuously working to improve ways to administer medicines and active ingredients. For several years, therefore, Merck Serono has been developing novel, more user-friendly injection devices, which make injections less painful and at the same time more reliable for patients than conventional, pre-filled syringes. In addition, these products make it easier for medical staff to check whether patients adhere to their therapeutic regimen. Examples are the Gonal-f® RFF Rebiject™ injection device and [...]
